[
  {
    "ts": null,
    "headline": "Pfizer (PFE) Outperforms Broader Market: What You Need to Know",
    "summary": "In the latest trading session, Pfizer (PFE) closed at $25.32, marking a +1.12% move from the previous day.",
    "url": "https://finnhub.io/api/news?id=92572f31833da5d7e8c4ab200f6f45cd1ef3d645897c8972074e3d417903e300",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751492704,
      "headline": "Pfizer (PFE) Outperforms Broader Market: What You Need to Know",
      "id": 135735862,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "In the latest trading session, Pfizer (PFE) closed at $25.32, marking a +1.12% move from the previous day.",
      "url": "https://finnhub.io/api/news?id=92572f31833da5d7e8c4ab200f6f45cd1ef3d645897c8972074e3d417903e300"
    }
  },
  {
    "ts": null,
    "headline": "Kennedy Expands RSV Vaccine Recommendations. Moderna, Pfizer Shares Are Up.",
    "summary": "The RSV vaccine is now recommended for adults aged 50 to 59 who are at a high risk of severe infection.",
    "url": "https://finnhub.io/api/news?id=d06246555bc8354a1e1405384930dbdbe3ce363d5037ee0f5edf593def1d4759",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751488380,
      "headline": "Kennedy Expands RSV Vaccine Recommendations. Moderna, Pfizer Shares Are Up.",
      "id": 135716854,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The RSV vaccine is now recommended for adults aged 50 to 59 who are at a high risk of severe infection.",
      "url": "https://finnhub.io/api/news?id=d06246555bc8354a1e1405384930dbdbe3ce363d5037ee0f5edf593def1d4759"
    }
  },
  {
    "ts": null,
    "headline": "Magnificent 7 Now The Troubling 3, Underscores Market Weakness",
    "summary": "Michael Kramer from Mott Capital Management and Reading The Markets on the first half of the first half of the year - market recovery has mostly been surprising.",
    "url": "https://finnhub.io/api/news?id=acf0e27a8b65b4d954d835f70f15677f419583c4bf34e556d9252940ce3a66bc",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751479200,
      "headline": "Magnificent 7 Now The Troubling 3, Underscores Market Weakness",
      "id": 135716715,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2218761418/image_2218761418.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Michael Kramer from Mott Capital Management and Reading The Markets on the first half of the first half of the year - market recovery has mostly been surprising.",
      "url": "https://finnhub.io/api/news?id=acf0e27a8b65b4d954d835f70f15677f419583c4bf34e556d9252940ce3a66bc"
    }
  },
  {
    "ts": null,
    "headline": "Huge Unusual Volume in Pfizer Put Options Signals Investors Bullish Outlook",
    "summary": "Large unusual trading volume in Pfizer put options that expire 30 days from now signals investors' bullish outlook on PFE stock. It trades for just over 8 times earnings, well below its 10-year historical average P/E ratio.",
    "url": "https://finnhub.io/api/news?id=850d2ad266e150c5891885db06e833202ce22a7115ba16aac92e63efb3f2aa80",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751477402,
      "headline": "Huge Unusual Volume in Pfizer Put Options Signals Investors Bullish Outlook",
      "id": 135716855,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Large unusual trading volume in Pfizer put options that expire 30 days from now signals investors' bullish outlook on PFE stock. It trades for just over 8 times earnings, well below its 10-year historical average P/E ratio.",
      "url": "https://finnhub.io/api/news?id=850d2ad266e150c5891885db06e833202ce22a7115ba16aac92e63efb3f2aa80"
    }
  },
  {
    "ts": null,
    "headline": "Robert F. Kennedy Jr. Just Did The Unexpected. He Helped Moderna.",
    "summary": "Moderna stock popped Wednesday after the CDC recommended the company's RSV vaccine for at-risk adults in their 50s.",
    "url": "https://finnhub.io/api/news?id=9e7d87f80fef22abc0356d3a33de6912815b81eb1ebbed8060e7df3c976b1735",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751476731,
      "headline": "Robert F. Kennedy Jr. Just Did The Unexpected. He Helped Moderna.",
      "id": 135716856,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Moderna stock popped Wednesday after the CDC recommended the company's RSV vaccine for at-risk adults in their 50s.",
      "url": "https://finnhub.io/api/news?id=9e7d87f80fef22abc0356d3a33de6912815b81eb1ebbed8060e7df3c976b1735"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Inc. stock outperforms competitors on strong trading day",
    "summary": "Pfizer Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=2b0f12b2bd38c27551ae4a12fa301278723b7a2ae54c2dc0293b83afac74e557",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751474160,
      "headline": "Pfizer Inc. stock outperforms competitors on strong trading day",
      "id": 135732075,
      "image": "",
      "related": "PFE",
      "source": "MarketWatch",
      "summary": "Pfizer Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=2b0f12b2bd38c27551ae4a12fa301278723b7a2ae54c2dc0293b83afac74e557"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer : June Social Media Round-Up—Father’s Day, 2024 Impact Report, and MoreUpdates & StatementsAlbert BourlaArtificial IntelligenceCancerDiseases & ConditionsResearch • • •",
    "summary": "Both the weather and Pfizer's social media were heating up during the month of June. On our corporate channels, we shared empowering patient stories, presented positive data at...",
    "url": "https://finnhub.io/api/news?id=fb18c3343dc830fef5ccd24070ba76b9b33459f511bf0645a07c67acc3bf3804",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751473627,
      "headline": "Pfizer : June Social Media Round-Up—Father’s Day, 2024 Impact Report, and MoreUpdates & StatementsAlbert BourlaArtificial IntelligenceCancerDiseases & ConditionsResearch • • •",
      "id": 135715909,
      "image": "",
      "related": "PFE",
      "source": "Finnhub",
      "summary": "Both the weather and Pfizer's social media were heating up during the month of June. On our corporate channels, we shared empowering patient stories, presented positive data at...",
      "url": "https://finnhub.io/api/news?id=fb18c3343dc830fef5ccd24070ba76b9b33459f511bf0645a07c67acc3bf3804"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer terminates study of CD47 in blood cancer due to low recruitment",
    "summary": "Pfizer is yet another company facing challenges with CD47 studies.",
    "url": "https://finnhub.io/api/news?id=9434882625f3ea2825b00e282416a1c19e6f2dd6c1f5ce557e3769e4f62609e3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751454542,
      "headline": "Pfizer terminates study of CD47 in blood cancer due to low recruitment",
      "id": 135711278,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer is yet another company facing challenges with CD47 studies.",
      "url": "https://finnhub.io/api/news?id=9434882625f3ea2825b00e282416a1c19e6f2dd6c1f5ce557e3769e4f62609e3"
    }
  },
  {
    "ts": null,
    "headline": "Semaglutide Market Forecast Report 2025-2033 | Growth Accelerates Amid Rising Awareness, Regulatory Approvals, and Strong Pipeline Advancements",
    "summary": "The Semaglutide market is projected to expand from US$ 27.15 billion in 2024 to US$ 61.7 billion by 2033, with a CAGR of 9.55% from 2025. Driven by rising obesity and type 2 diabetes incidences, the market for semaglutide, a GLP-1 receptor agonist, is growing due to its efficacy in glycemic control and weight management. Brand names like Ozempic, Rybelsus, and Wegovy underscore its role in improving health outcomes. Increased awareness, approvals, and advanced delivery systems play pivotal roles",
    "url": "https://finnhub.io/api/news?id=cacaeab5a9d58cf9cbe3fc3c6cccefcd299e1467220dd1cf04e9ee6d8b3b85ad",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751449380,
      "headline": "Semaglutide Market Forecast Report 2025-2033 | Growth Accelerates Amid Rising Awareness, Regulatory Approvals, and Strong Pipeline Advancements",
      "id": 135711116,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The Semaglutide market is projected to expand from US$ 27.15 billion in 2024 to US$ 61.7 billion by 2033, with a CAGR of 9.55% from 2025. Driven by rising obesity and type 2 diabetes incidences, the market for semaglutide, a GLP-1 receptor agonist, is growing due to its efficacy in glycemic control and weight management. Brand names like Ozempic, Rybelsus, and Wegovy underscore its role in improving health outcomes. Increased awareness, approvals, and advanced delivery systems play pivotal roles",
      "url": "https://finnhub.io/api/news?id=cacaeab5a9d58cf9cbe3fc3c6cccefcd299e1467220dd1cf04e9ee6d8b3b85ad"
    }
  }
]